Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Asset Writedowns and Impairment (2017 - 2020)

Rocket Pharmaceuticals' Asset Writedowns and Impairment history spans 1 years, with the latest figure at -$1000.0 for Q2 2020.

  • For Q2 2020, Asset Writedowns and Impairment changed N/A year-over-year to -$1000.0; the TTM value through Dec 2023 reached -$1000.0, down 101.61%, while the annual FY2025 figure was $262000.0, N/A changed from the prior year.
  • Asset Writedowns and Impairment for Q2 2020 was -$1000.0 at Rocket Pharmaceuticals, down from $63000.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $63000.0 in Q1 2020 and bottomed at -$1000.0 in Q2 2020.